Get the Stockscreener App
2.025
0.49%
-0.01
Maravai Lifesciences Holdings Inc stock is traded at $2.025, with a volume of 553.19K.
It is down -0.49% in the last 24 hours and down -22.12% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
See More
Previous Close:
$2.035
Open:
$2.04
24h Volume:
553.19K
Relative Volume:
0.32
Market Cap:
$291.55M
Revenue:
$288.95M
Net Income/Loss:
$-119.03M
P/E Ratio:
-2.2488
EPS:
-0.9005
Net Cash Flow:
$60.67M
1W Performance:
-13.46%
1M Performance:
-22.12%
6M Performance:
-55.79%
1Y Performance:
-77.75%
1-Day Range:
$1.99
$2.06
1-Week Range:
$1.99
$2.40
52-Week Range:
$1.665
$9.95
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
2.025 | 336.90M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.39 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.23 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.14 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
294.82 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-19-24 | Initiated | Guggenheim | Neutral |
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-10-24 | Initiated | Craig Hallum | Buy |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-09-23 | Downgrade | Goldman | Buy → Neutral |
| Jan-05-23 | Downgrade | UBS | Buy → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Initiated | Credit Suisse | Outperform |
| Dec-15-20 | Initiated | Goldman | Buy |
| Dec-15-20 | Initiated | Jefferies | Buy |
| Dec-15-20 | Initiated | Robert W. Baird | Outperform |
| Dec-15-20 | Initiated | Stifel | Buy |
| Dec-15-20 | Initiated | William Blair | Outperform |
| Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
When is Maravai LifeSciences Holdings Inc. stock expected to show significant growthMaximize returns with strategic stock selection - Jammu Links News
How many analysts rate Maravai LifeSciences Holdings Inc. as a “Buy”Discover stocks with massive upside potential - Jammu Links News
Why is Maravai LifeSciences Holdings Inc. stock attracting strong analyst attentionHigh-yield market plays - Jammu Links News
Is Maravai LifeSciences Holdings Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Does Maravai LifeSciences Holdings Inc. stock perform well during market downturnsFree Trend-Following Techniques - Jammu Links News
How does Maravai LifeSciences Holdings Inc. compare to its industry peersSkyrocketing profit margins - Jammu Links News
What are the latest earnings results for Maravai LifeSciences Holdings Inc.Outstanding investment returns - Jammu Links News
Is Maravai LifeSciences Holdings Inc. a growth stock or a value stockCapitalize on fast-moving market trends - Jammu Links News
Has Maravai LifeSciences Holdings Inc. found a price floorWatchlist Generator With Real-Time Entry - Newser
Pattern recognition hints at Maravai LifeSciences Holdings Inc. upsideFree Beginner Friendly Stock Selection Guide - Newser
Is Maravai LifeSciences Holdings Inc. meeting your algorithmic filter criteriaFree Swing Trading Entry Point Signals - Newser
Wells Fargo Reiterates a Buy Rating on Maravai LifeSciences Holdings (MRVI) - Insider Monkey
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
Price momentum metrics for Maravai LifeSciences Holdings Inc. explainedFree Capital Protection Trading Strategies - Newser
Why Maravai LifeSciences Holdings Inc. stock attracts strong analyst attention - metal.it
Published on: 2025-07-28 23:24:21 - metal.it
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025 - GlobeNewswire
Maravai LifeSciences to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 11 - Quiver Quantitative
Should I hold or sell Maravai LifeSciences Holdings Inc. stock in 2025Breakthrough capital growth - Jammu Links News
What are the technical indicators suggesting about Maravai LifeSciences Holdings Inc.Get real-time updates on market trends - jammulinksnews.com
What is the dividend policy of Maravai LifeSciences Holdings Inc. stockDiscover top stock picks for aggressive growth - Jammu Links News
What is the risk reward ratio of investing in Maravai LifeSciences Holdings Inc. stockFree Capital Growth Strategies - Jammu Links News
What drives Maravai LifeSciences Holdings Inc. stock pricePowerful market insights - PrintWeekIndia
Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc.MRVI - FinancialContent
What analysts say about Maravai LifeSciences Holdings Inc. stockGame-changing returns - PrintWeekIndia
Is Maravai LifeSciences Holdings Inc. a good long term investmentTremendous portfolio expansion - PrintWeekIndia
Is Maravai LifeSciences Holdings Inc. stock overhyped or has real potentialRapid market gains - jammulinksnews.com
What institutions are buying Maravai LifeSciences Holdings Inc. stock nowFree Trend-Following Techniques - jammulinksnews.com
MARAVAI LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc.MRVI - Business Wire
Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Holdings Inc. Stock Analysis and ForecastMarket-leading growth rates - Jammu Links News
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
16,587 Shares in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Purchased by Teacher Retirement System of Texas - Defense World
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):